SSA
VIVO

Schonfeld Strategic Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,909
Closed -$394K – 1761
2020
Q2 		$394K Buy
+16,909
New +$245K 0.01% 894
2017
Q1 		– Sell
-13,470
Closed -$238K – 774
2016
Q4 		$238K Buy
+13,470
New +$237K 0.03% 467

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Schonfeld Strategic Advisors's VIVO Position: Q3 2020 in Review

Schonfeld Strategic Advisors sold out of Meridian Bioscience Inc (VIVO) in Q3 2020, closing a stake of 16,909 shares — an estimated $394K sold.

Schonfeld Strategic Advisors first reported a position in VIVO in Q4 2016 and held it in 2 quarters. The position peaked at $394K in Q2 2020. 191 funds tracked by Wall St. Rank hold VIVO as of Q3 2020.

  • Schonfeld Strategic Advisors reported no remaining Meridian Bioscience Inc position as of Q3 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,909 Meridian Bioscience Inc shares in Q3 2020, an estimated $394K.
  • Schonfeld Strategic Advisors first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Meridian Bioscience Inc position peaked at $394K in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.